Nu Image Medical Semaglutide Review

Nu Image Medical puts its regulatory disclosure in the same breath as its price, which is the test most operators in this category fail. Our research (September 1, 2026) found a long-menu telehealth practice with accurate compounding language and thin published protocol detail.

The Disclosure Sits Next to the Price

Most sites put "not FDA approved" in a footer. Nu Image puts it in the product description a buyer actually reads:

"Explore cash-pay semaglutide, a GLP-1 medication, as a weekly injection from $99/month or a daily rapid-dissolve tablet. A licensed provider determines eligibility; compounded semaglutide is not FDA-approved."

Products are labelled "Compounded Medication / Rx Only." The full disclosure names both compounding pathways explicitly:

"Compounded medications are prepared by state-licensed 503A/503B compounding pharmacies. Compounded drugs are not reviewed or approved by the FDA for safety, efficacy, or quality. Prescription products require an online consultation with a licensed healthcare provider who will determine if a prescription is appropriate."

Naming 503A and 503B rather than saying "a licensed pharmacy" shows the operator understands the distinction — though it does not say which applies to a given prescription, which is the follow-up question worth asking. The usual post-shortage point stands: with the tirzepatide shortage resolved in October 2024 and semaglutide in early 2025, lawful 503A compounding depends on a documented clinical reason for the individual patient.

Providers Licensed Where You Live

"Yes. Your assigned provider will be licensed in the state that you reside in."

"Prescription medications require a consultation with a licensed healthcare provider."

Coverage is 49 states. Prescribing is stated to be conditional on the provider determining appropriateness, and the medication is framed carefully — a GLP-1 receptor agonist "to support appetite regulation and metabolic health," which is accurate and avoids outcome promises.

Two Formulations

The weekly injection is the main product at from $99/month. A daily rapid-dissolve tablet is also offered. Worth understanding: there is an FDA-approved oral semaglutide (Rybelsus), but it is a distinct formulation with its own absorption profile, and a compounded rapid-dissolve tablet is not that product and has no approved counterpart. Bioavailability and dose equivalence for compounded sublingual or orally dissolving semaglutide are not established. The injection is the better-understood option unless there is a specific reason to avoid needles.

The Breadth Question

Nu Image Medical is a wide-menu operation — "online medical weight loss, hormones, and ED" — rather than a focused GLP-1 practice. That is not a fault in itself, and a practice already running hormone and men's-health telehealth has real clinical infrastructure. But it means GLP-1 care is one line in a catalogue rather than the organising purpose, and the published protocol detail reflects that.

What Is Not Published

No specific pharmacy is named, and while both 503A and 503B are referenced, which one fills a given prescription is not stated. No dose-tier pricing — "$99/month" is a starting figure with no published schedule for what a maintenance dose costs, which is the central pricing gap. No BMI or clinical eligibility criteria. No lab requirements, titration protocol or monitoring cadence. No refund or cancellation terms, and no founding year.